AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $26.2 million for the first quarter of 2026, reflecting strong launches in the US and most recently the UKCompany achieves positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results